TABLE 1.
Demographic data. The percentages refer to the total number of observations. Missing data are not explicitly stated in the table. Age at Visit 1 was the age at index sting, age at Visit 2 was the age when venom immunotherapy was started
|
Visit 1 (n = 1,425) pre‐treatment |
Visit 2 (n = 1,342) up‐dosing phase |
Visit 3 (n = 1,186) maintenance phase |
|
|---|---|---|---|
| Age range (mean age) [years] | 35–80 (52) | 35–84 (54) | 36–85 (55) |
| Sex, n (%) | |||
| Male | 810 (56.8) | 774 (57.7) | 679 (57.3) |
| Female | 615 (43.2) | 568 (42.3) | 507 (42.7) |
| Grade of SSR (index sting), n (%) | |||
| Grade I | 122 (8.6) | .. | .. |
| Grade II | 700 (49.1) | .. | .. |
| Grade III | 589 (41.3) | .. | .. |
| Grade IV | 14 (1.0) | .. | .. |
| Antihypertensive treatment, n (%) | |||
| No medication | 1,035 (72.6) | 1,001 (74.6) | 886 (74.7) |
| β‐blockers | 148 (10.4) | 123 (9.2) | 105 (8.9) |
| ACEI | 169 (11.9) | 159 (11.9) | 136 (11.5) |
| β‐blockers and ACEI | 71 (5.0) | 58 (4.3) | 55 (4.6) |
| Cardiovascular disease, n (%) | |||
| No disease | 845 (59.3) | 801 (59.7) | 715 (60.3) |
| Coronary heart disease or hypertension | 571 (40.1) | 533 (39.7) | 463 (39.0) |
| Causal venom, n (%) | |||
| Bee | 320 (22.5) | 351 (26.2) | 297 (25.0) |
| Vespid | 838 (58.8) | 923 (68.8) | 829 (69.9) |
| Bee & vespid | 206 (14.5) | 67 (5.0) | 57 (4.8) |
| Basal tryptase level, n (%) | |||
| ≤11.4 µg/L | 1,159 (81.3) | 1,092 (81.4) | 972 (82.0) |
| >11.4 µg/L | 127 (8.9) | 121 (9.0) | 108 (9.1) |